Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Promyelocytic Leukemia
Research on acute promyelocytic leukemia published by scientists at Tor Vergata University
April 20th, 2008
According to recent research published in the journal Current Opinion in Hematology, "Purpose of review This review addresses use of monoclonal antibodies and Immunoconjugates to treat acute myeloid leukemia. Recent findings Monoclonal antibodies used in acute myeloid leukemia have been directed against the antigens CD33, CD45, and CD66." "Unconjugated monoclonal antibodies such as lintuzumab have modest activity against overt acute myeloid leukemia but can eliminate minimal residual disease in acute promyelocytic leukemia. Most experience with immunoconjugates is with gemtuzumab ozogamicin, an anti-CD33 monoclonal antibody linked to the potent antitumor...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-20)
|
